Unbound MEDLINE

Crystal structure determination of mebendazole form A using high-resolution synchrotron X-ray powder diffraction data. Journal of pharmaceutical sciences [J Pharm Sci] Journal article

 
TitleCrystal structure determination of mebendazole form A using high-resolution synchrotron X-ray powder diffraction data.
Author(s)Ferreira FF, Antonio SG, Rosa PC, Paiva-Santos CD 
InstitutionLaboratório Nacional de Luz Síncrotron, Caixa Postal 6192, CEP: 13083-970, Campinas, SP, Brazil.
SourceJ Pharm Sci 2009 Aug 4.
AbstractThe crystal structure determination of mebendazole form A, an anthelmintic drug, was performed for the first time by applying the DASH software program to synchrotron X-ray powder diffraction data, and supported by a satisfying Rietveld fit. This polymorph of mebendazole crystallizes in a triclinic $(P\bar 1)$ space group, with unit-cell parameters a = 5.5044(2) A, b = 11.2872(2) A, c = 12.5276(5) A, alpha = 66.694(2) degrees , beta = 82.959(2) degrees , gamma = 78.443(2) degrees , V = 699.52(5) A(3), Z = 2, M = 295.293 g mol(-1), rho(calc) = 1.4021 g cm(-3), and rho(meas) = 1.3935(66) g cm(-3), which were obtained by means of the unit-cell formula weight and a picnometric measurement, respectively. The goodness-of-fit and R-factors were, respectively: chi(2) = 1.746, $R_{\rm F};2$ = 1.69%, R(wp) = 5.72%, and R(p) = 4.37%. A weak nonclassical hydrogen bond involving the atoms N(3)--H(23)$\cdots$O(11) may be responsible for the greater stability of the polymorphic form A of mebendazole due to the strongest electronegativity of nitrogen. (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19655377
  
Advertise on this site.